专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008005910A2 PYRIDONE/HYDROXYPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：吡啶酮/羟基吡啶11-羟基脱氢酶脱氢酶I型抑制剂
公开(公告)号：WO2008005910A2
公开(公告)日：2008-01-10
申请号：PCT/US2007/072626
申请日：2007-07-02
申请人： BRISTOL-MYERS SQUIBB COMPANY , ROBL, Jeffrey A. , WU, Shung C. , YOON, David S.
发明人： ROBL, Jeffrey A. , WU, Shung C. , YOON, David S.
IPC分类号： C07D217/24 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04 , A61K31/4355 , A61P3/00
CPC分类号： C07D217/24 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R 1 are defined herein.
摘要翻译：提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。这些新化合物具有结构式（I）对映异构体，非对映体，溶剂合物，盐，互变异构体或前药，其中A，W，X，Y和R 1在本文中定义。

2. 发明申请

WO2006113261A3 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I 审中-公开
标题翻译： 11-β羟基类固醇脱氢酶I型抑制剂
公开(公告)号：WO2006113261A3
公开(公告)日：2006-11-30
申请号：PCT/US2006013610
申请日：2006-04-12
申请人： SQUIBB BRISTOL MYERS CO , LI JAMES J , HAMANN LAWRENCE G , RUAN ZHEMING , COOPER CHRISTOPHER B , WU SHUNG C , SIMPKINS LIGAYA M , WANG HAIXIA , NAYEEM AKBAR , KRYSTEK STANLEY R JR
发明人： LI JAMES J , HAMANN LAWRENCE G , RUAN ZHEMING , COOPER CHRISTOPHER B , WU SHUNG C , SIMPKINS LIGAYA M , WANG HAIXIA , NAYEEM AKBAR , KRYSTEK STANLEY R JR
IPC分类号： C07D401/12 , A61K31/444 , A61P3/00 , A61P9/00 , A61P25/00 , C07D401/04 , C07D401/14
CPC分类号： C07D213/70 , A61K31/421 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/506 , C07D213/71 , C07D213/81 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D487/04 , C07D487/08
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R 6 , R 7 , and R 8 are defined herein.
摘要翻译：提供了11-β-羟基类固醇脱氢酶I型抑制剂的新型化合物。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。这些新化合物具有以下结构：（I）或其立体异构体或前药或药学上可接受的盐，其中G，L，Q，Z，R 6，R 7，和本文中定义了R SUB 8。

3. 发明申请

WO2006113261A2 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I 审中-公开
标题翻译： 11-羟基脱氢酶脱氢酶I型抑制剂
公开(公告)号：WO2006113261A2
公开(公告)日：2006-10-26
申请号：PCT/US2006/013610
申请日：2006-04-12
申请人： BRISTOL-MYERS SQUIBB COMPANY , LI, James, J. , HAMANN, Lawrence, G. , RUAN, Zheming , COOPER, Christopher, B. , WU, Shung, C. , SIMPKINS, Ligaya, M. , WANG, Haixia , NAYEEM, Akbar , KRYSTEK, Stanley, R., Jr.
发明人： LI, James, J. , HAMANN, Lawrence, G. , RUAN, Zheming , COOPER, Christopher, B. , WU, Shung, C. , SIMPKINS, Ligaya, M. , WANG, Haixia , NAYEEM, Akbar , KRYSTEK, Stanley, R., Jr.
IPC分类号： C07D401/12 , C07D401/14 , C07D401/04 , A61K31/444
CPC分类号： C07D213/70 , A61K31/421 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/506 , C07D213/71 , C07D213/81 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D487/04 , C07D487/08
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R 6 , R 7 , and R 8 are defined herein.
摘要翻译：提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。这些新化合物具有以下结构：（I）或其立体异构体或前药或其药学上可接受的盐，其中G，L，Q，Z，R 6，R 7和本文定义R 8。

4. 发明申请

WO0237937A3 ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：可用作丝氨酸蛋白酶抑制剂的酸衍生物
公开(公告)号：WO0237937A3
公开(公告)日：2002-08-29
申请号：PCT/US0149952
申请日：2001-11-07
申请人： SQUIBB BRISTOL MYERS CO , BISACCHI GREGORY S , SUTTON JAMES C JR , WU SHUNG C
发明人： BISACCHI GREGORY S , SUTTON JAMES C JR , WU SHUNG C
IPC分类号： A61K31/192 , A61K31/402 , A61K31/4458 , A61K31/4545 , A61K31/55 , A61K45/00 , A61K45/06 , A61P7/02 , A61P29/00 , A61P37/00 , C07C257/18 , C07D207/16 , C07D211/60 , C07D223/06 , C07D401/12 , A61K31/155 , A61K31/445
CPC分类号： C07D401/12 , A61K45/06 , C07B2200/07 , C07C257/18 , C07D207/16 , C07D211/60 , C07D223/06
摘要： Compounds of formula I and II, or pharmaceutically-acceptable salts thereof , are useful as inhibitors of Factor VIIa, Factor IXa, Factor Xa, Factor FXIa, tryptase, and urokinase, wherein ring B is phenyl or pyridyl, L is a linker, and R1 R27, W, Z1 , and Z2 are as defined in the specification.
摘要翻译：式I和II的化合物或其药学上可接受的盐可用作因子VIIa，因子IXa，因子Xa，因子FXIa，类胰蛋白酶和尿激酶的抑制剂，其中环B是苯基或吡啶基，L是连接体，和 R1 R27，W，Z1和Z2如说明书中所定义。

5. 发明申请

WO0242273A2 ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：可用作丝氨酸蛋白酶抑制剂的酸衍生物
公开(公告)号：WO0242273A2
公开(公告)日：2002-05-30
申请号：PCT/US0146884
申请日：2001-11-07
申请人： SQUIBB BRISTOL MYERS CO , BISACCHI GREGORY S , SUTTON JAMES C JR , SLUSARCHYK WILLIAM A , TREUNER UWE D , ZHAO GUOHUA , CHENEY DANIEL L , WU SHUNG C , SHI YAN
发明人： BISACCHI GREGORY S , SUTTON JAMES C JR , SLUSARCHYK WILLIAM A , TREUNER UWE D , ZHAO GUOHUA , CHENEY DANIEL L , WU SHUNG C , SHI YAN
IPC分类号： C07D333/38 , A61K31/166 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/4184 , A61K31/421 , A61K31/423 , A61K31/426 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/4462 , A61K31/4465 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/517 , A61K31/55 , A61K45/00 , A61K45/06 , A61P1/04 , A61P1/16 , A61P1/18 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P21/04 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/04 , A61P35/00 , A61P37/08 , A61P43/00 , C07C233/78 , C07C257/18 , C07D207/16 , C07D209/08 , C07D209/44 , C07D211/26 , C07D211/60 , C07D213/73 , C07D213/81 , C07D223/06 , C07D235/08 , C07D235/30 , C07D261/20 , C07D263/32 , C07D277/20 , C07D277/40 , C07D277/82 , C07D307/68 , C07D307/79 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/10 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D471/04 , C07D213/00
CPC分类号： C07D401/12 , A61K45/06 , C07B2200/07 , C07C257/18 , C07D207/16 , C07D211/60 , C07D223/06
摘要： Compounds having the formula (I), are useful as serine protease inhibitors, more particularly inhibitors of Factors VIIa, Ixa, Xa, and/or Xia, wherein ring B is phenyl or pyridyl, W is preferably C(=O)NR4R5, L is a linker group, X2 comprises nitrogen or carbon, Z is an optionally-substituted monocyclic or bicyclic ring system, and R1, R2, R3, R4, R5 and R6 are as defined in the specification.
摘要翻译：具有式（I）的化合物可用作丝氨酸蛋白酶抑制剂，更具体地可用于因子VIIa，Ixa，Xa和/或Xia的抑制剂，其中环B是苯基或吡啶基，W优选为C（= O）NR 4 R 5，L 是连接基团，X 2包括氮或碳，Z是任选取代的单环或双环环系，R1，R2，R3，R4，R5和R6如说明书中所定义。

6. 发明申请

WO0127107A3 HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD 审中-公开
标题翻译：杂环钠/离子交换剂抑制剂和方法
公开(公告)号：WO0127107A3
公开(公告)日：2002-01-24
申请号：PCT/US0027461
申请日：2000-10-02
申请人： SQUIBB BRISTOL MYERS CO , AHMAD SALEEM , WU SHUNG C , NEIL STEVEN V O , NGU KHEHYONG , ATWAL KARNAIL S
发明人： AHMAD SALEEM , WU SHUNG C , O'NEIL STEVEN V , NGU KHEHYONG , ATWAL KARNAIL S
IPC分类号： C07D233/64 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4168 , A61K31/4172 , A61K31/4178 , A61K31/4196 , A61K31/4245 , A61K31/426 , A61K31/427 , A61K31/437 , A61K31/4427 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K45/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P13/12 , A61P19/10 , A61P25/28 , A61P29/00 , A61P43/00 , C07D231/38 , C07D233/54 , C07D233/84 , C07D233/88 , C07D239/48 , C07D277/20 , C07D277/40 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/10 , C07D405/08 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/08 , C07D417/04 , C07D417/08 , C07D417/14 , C07D471/02 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04
CPC分类号： C07D233/56 , C07D233/64 , C07D233/88 , C07D239/49 , C07D277/20 , C07D277/40 , C07D401/04 , C07D401/14 , C07D403/08 , C07D405/08 , C07D409/14 , C07D417/08 , C07D471/04 , C07D487/04
摘要： Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure (I) wherein n is 1 to 5; X is N or C-R wherein R is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group, R , R , R and R are as defined herein, and where X is N, R is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.
摘要翻译：提供了具有其中n为1至5的结构（I）的钠/质子交换（NHE）抑制剂的杂环; X是N或C-R 5，其中R 5是H，卤素，烯基，炔基，烷氧基，烷基，芳基或杂芳基; Z是杂芳基，R 1，R 2，R 3和R 4如本文所定义，并且其中X是N，R 1优选是芳基或杂芳基，并且可用作抗心绞痛和心脏保护剂。此外，提供了使用上述杂环衍生物预防或治疗心绞痛，心脏功能障碍，心肌坏死和心律不齐的方法。

7. 发明申请

WO1996028427A1 BENZAMIDINE DERIVATIVES THEIR PREPARATION AND THEIR USE AS ANTI-COAGULANTS 审中-公开
标题翻译：苯扎林衍生物他们的制备及其作为抗凝剂的使用
公开(公告)号：WO1996028427A1
公开(公告)日：1996-09-19
申请号：PCT/US1996002641
申请日：1996-03-08
申请人： BERLEX LABORATORIES, INC. , BUCKMAN, Brad, O. , DAVEY, David, D. , GUILFORD, William, J. , MORRISSEY, Michael, M. , NG, Howard, P. , PHILLIPS, Gary, B. , WU, Shung, C. , XU, Wei
发明人： BERLEX LABORATORIES, INC.
IPC分类号： C07D213/69
CPC分类号： C07D213/69 , C07C257/18 , C07C275/42 , C07D213/74 , C07D213/79 , C07D213/81 , C07D213/82 , C07D231/12 , C07D233/56 , C07D239/52 , C07D241/18 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14
摘要： This invention is directed to benzamidine derivatives which are useful as anti-coagulants. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat disease-states characterized by thrombotic activity. Accordingly, in one aspect, this invention provides compounds selected from the group consisting of formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), wherein: A is -C(R )= or -N=; Z and Z are independently -O-, -N(R )-, -S-, or -OCH2-; R and R are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, -N(R )R , -C(O)OR , -C(O)N(R )CH2C(O)N(R )R , -N(R )C(O)N(R )R , -N(R )C(O)R , -N(R )S(O)2R , or -N(R )C(O)N(R )CH2C(O)N(R )R ; R is hydrogen; halo; alkyl; haloalkoxy; -OR ; -C(O)OR ; -C(O)N(R )R ; -N(R )R ; -C(O)N(R )(CH2)mC(O)OR (where m is 0 to 3); -N(R )(CH2)nC(O)OR (where n is 1 to 3); -N((CH2)nN(R )R )(CH2)nC(O)OR (where each n is 1 to 3); -O(CH2)nC(O)N(R )R (where n is 1 to 3); -O(CH2)pC(O)OR (where p is 1 to 6); -N(R )(CH2)nC(O)N(R )(CH2)nC(O)OR (where each n is independently 1 to 3); morpholin-4-yl; 3-tetrahydrofuranoxyl; etc.; R and R are independently hydrogen, halo, alkyl, nitro, -OR , -C(O)OR , -C(O)N(R )R , -N(R )R , -N(H)C(O)R , or -N(H)S(O)2R ; R is -C(NH)NH2, -C(NH)N(H)OR , -C(NH)N(H)C(O)OR , -C(NH)N(H)S(O)2R , -C(NH)N(H)C(O)N(R )R , or -C(NH)N(H)C(O)R ; R is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, -OR , -C(NH)NH2, -C(NH)NHOH, -C(O)R , -(CH2)mC(O)N(R )R (where m is 0 to 3), -CH(OH)C(O)N(R )R , -(CH2)mN(R )R (where m is 0 to 3), -(CH2)mC(O)OR (where m is 0 to 3), -N(H)C(O)R , (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl); each R and R is independently hydrogen alkyl, aryl, or aralkyl; R is hydrogen, alkyl, aryl, aralkyl, 1-pyrrolidinyl, 4-morpolinyl, 4-piperazinyl, 4-(N-methyl)piperazinyl, or piperidin-1-yl; R is hydrogen, alkyl or halo; and R is alkyl, aryl or aralkyl; or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及可用作抗凝剂的苯甲脒衍生物。本发明还涉及含有本发明化合物的药物组合物，以及使用该化合物治疗以血栓形成活性为特征的疾病状态的方法。因此，一方面，本发明提供了选自式（I），（II），（III），（IV），（V），（VI），（VII）和（VIII）其中：A是-C（R 11）=或-N =; Z 1和Z 2独立地是-O - ， - N（R 8） - ， - S - 或-OCH 2 - ; R 1和R 3独立地是氢，卤素，烷基，卤代烷基，烷氧基，卤代烷氧基，硝基，-N（R 8）R 9，-C（O）OR 8，-C （O）N（R 8）CH 2 C（O）N（R 8）R 9，-N（R 8）C（O）N（R 8）R 9， -N（R 8）C（O）R 8，-N（R 8）S（O）2 R 12或-N（R 8）C（O） <8>）CH 2 C（O）N（R <8>）R <9>; R 2是氢; 光环; 烷基; 卤代烷氧基; -OR <8>; -C（O）OR <8>; -C（O）N（R <8>）R <9>; -N（R <8>）R <9>; -C（O）N（R 8）（CH 2）m C（O）OR 8（其中m为0至3）; -N（R 8）（CH 2）n C（O）OR 8（其中n为1至3）; -N（（CH 2）n N（R 8）R 9）（CH 2）n C（O）OR 8（其中n为1至3）; -O（CH 2）n C（O）N（R 8）R 9（其中n为1至3）; -O（CH 2）p C（O）OR 8（其中p为1至6）; -N（R 8）（CH 2）n C（O）N（R 8）（CH 2）n C（O）OR 8（其中每个n独立地为1至3）; 吗啉-4-基; 3- tetrahydrofuranoxyl; 等等。; R 4和R 7独立地是氢，卤素，烷基，硝基，-OR 8，-C（O）OR 8，-C（O）N（R 8）R 9 ，-N（R 8）R 9，-N（H）C（O）R 8或-N（H）S（O）2 R 12; R 5是-C（NH）NH 2，-C（NH）N（H）OR 8，-C（NH）N（H）C（O）OR 12，-C（NH）（H）S（O）2 R 12，-C（NH）N（H）C（O）N（R 8）R 9或-C（NH）N（H））R <8>; R 6是卤素，烷基，卤代烷基，卤代烷氧基，硝基，氨基，脲基，胍基，-OR 8，-C（NH）NH 2，-C（NH）NHOH，-C（O）， - （CH 2）m C（O）N（R 8）R 9（其中m为0至3），-CH（OH）C（O）N（R 8）R 9， - （CH2）mN（R8）R9（其中m为0至3）， - （CH2）mC（O）OR 8（其中m为0至3），-N（H） C（O）R 8，（1,2） - 四氢嘧啶基（任选被烷基取代），（1,2） - 咪唑基（任选被烷基取代）或（1,2） - 咪唑啉基（任选被烷基）; 每个R 8和R 9独立地是烷基，芳基或芳烷基; R 10是氢，烷基，芳基，芳烷基，1-吡咯烷基，4-吗啉基，4-哌嗪基，4-（N-甲基）哌嗪基或哌啶-1-基; R 11是氢，烷基或卤素; 和R 12是烷基，芳基或芳烷基; 或其药学上可接受的盐。

8. 发明申请

WO2008005910A3 PYRIDONE/HYDROXYPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：吡啶酮/羟基吡啶11-β羟基类固醇脱氢酶I型抑制剂
公开(公告)号：WO2008005910A3
公开(公告)日：2008-03-20
申请号：PCT/US2007072626
申请日：2007-07-02
申请人： SQUIBB BRISTOL MYERS CO , ROBL JEFFREY A , WU SHUNG C , YOON DAVID S
发明人： ROBL JEFFREY A , WU SHUNG C , YOON DAVID S
IPC分类号： C07D217/24 , A61K31/4355 , A61P3/00 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04
CPC分类号： C07D217/24 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R 1 are defined herein.
摘要翻译：提供了11-β-羟基类固醇脱氢酶I型抑制剂的新型化合物。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。这些新型化合物具有结构式（I）的对映异构体，非对映异构体，溶剂合物，盐，互变异构体或前药，其中A，W，X，Y和R 1如本文所定义。

9. 发明申请

WO2002042273A3 ACID DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS 审中-公开
公开(公告)号：WO2002042273A3
公开(公告)日：2002-05-30
申请号：PCT/US2001/046884
申请日：2001-11-07
申请人： BRISTOL-MYERS SQUIBB COMPANY , BISACCHI, Gregory, S. , SUTTON, James, C., Jr. , SLUSARCHYK, William, A. , TREUNER, Uwe, D. , ZHAO, Guohua , CHENEY, Daniel, L. , WU, Shung, C. , SHI, Yan
发明人： BISACCHI, Gregory, S. , SUTTON, James, C., Jr. , SLUSARCHYK, William, A. , TREUNER, Uwe, D. , ZHAO, Guohua , CHENEY, Daniel, L. , WU, Shung, C. , SHI, Yan
IPC分类号： C07D401/12
摘要： Compounds having the formula (I), are useful as serine protease inhibitors, more particularly inhibitors of Factors VIIa, Ixa, Xa, and/or Xia, wherein ring B is phenyl or pyridyl, W is preferably C(=O)NR 4 R 5 , L is a linker group, X 2 comprises nitrogen or carbon, Z is an optionally-substituted monocyclic or bicyclic ring system, and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式